Synopsis: Hester Biosciences Limited has delivered a blowout financial performance for the fiscal year 2025-26. By focusing heavily on internal cost discipline, offloading a non-core subsidiary, and capitalising on its massive, high biosecurity manufacturing infrastructure, the animal healthcare leader turned a modest top-line increase into an absolute bottom-line explosion.
Hester Biosciences showcased a complete structural transformation. The overarching theme of the year was a deliberate shift toward margin expansion, balance sheet safety, and de-risking the business model from cyclical government tender calendars.
Hester Biosciences Limited is currently trading at Rs 2,140 after yesterday’s closing price of Rs 2,149. The stock opened at Rs 2,151 and striked a day high of Rs 2,193; the day’s low so far is Rs 2,109. The current market capitalisation of the company is Rs 1,821 crore, with a price-to-earnings ratio of 33.9 times, which is similar to the peer median industry ratio of 33.59 times.
Financials
Hester Biosciences reported a strong improvement in profitability in FY26, with PAT rising 99 percent to Rs 574.84 million, while EBITDA increased 53 percent to Rs 1,056.51 million. Revenue grew 7 percent to Rs 3,325.99 million, indicating significant operating leverage, as modest top line growth translated into sharp margin expansion.
Return metrics improved meaningfully, with ROE increasing to 17 percent (from 10 percent), supported by higher profitability. The company also declared a dividend of Rs 11 per share, reflecting improved earnings performance.
The company has achieved a sales CAGR of 9 percent and a profit CAGR of 8 percent over 5 years, with a 93 percent increase in profit in the latest period, from a growth perspective.
Strategic Actions and Balance Sheet Strengthening
During FY26, Hester Biosciences undertook key strategic initiatives, including a partial divestment in Texas Lifesciences, reducing its stake from 54.81 percent to 11 percent and booking an exceptional gain of Rs 69.96 million. The company also strengthened its balance sheet by reducing long-term borrowings from Rs 756.26 million to Rs 504.99 million, improving its debt-to-equity ratio to 0.19x from 0.31x. Additionally, Hester capitalised on its Fill-Finish and BSL-3 facilities, enhancing manufacturing capacity and enabling entry into higher-value biological segments.
Segment Performance and Revenue Mix Dynamics
Hester’s FY26 performance was driven by its poultry healthcare segment, which grew 24 percent year-on-year to Rs 2,060.79 million and represents nearly 71 percent of standalone revenue. Strong demand for poultry vaccines and regulatory approvals for the H9N2 avian influenza vaccine are expected to boost domestic and export opportunities.
Animal healthcare and petcare were hampered by government-led livestock vaccination delays. The company is expanding its private market portfolio to address these issues of veterinary therapeutics, nutritional supplements, and premium petcare offerings to build more stable, non-seasonal revenue streams.
Hester Biosciences Limited is an Indian animal healthcare company engaged in the manufacture of poultry and livestock vaccines and health products. The company has its own R&D department and specialist manufacturing facilities and develops products based on scientific research.
Hester markets poultry vaccines, large animal health and pet care products in Africa and other markets. Capacity expansion, regulatory approvals and a focus on high value biological products strengthen the company.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.inare their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
